AGP Executive Report
Last update: 8 hours agoLife Sciences Deal: GSK is buying Boston-based Nuvalent for $10.6 billion, adding three late-stage lung cancer programs, including two FDA-reviewed inhibitors (zidesamtinib and neladalkib) that could launch in 2026 if approved. Executive Moves: AdvanCell, a Massachusetts radiopharma company, named Justyna Kelly as CTO and François Gaudet as CSO as it scales U.S. operations. Innovation Pipeline: The Massachusetts Innovation Network’s “Eddies” named 2026 finalists across biotech and clean/climate categories, continuing its no-equity, no-cost mentorship push. Immigration & Labor: A federal judge in Boston struck down Trump’s $100,000 H-1B fee as an unlawful tax, a major hit to the administration’s immigration agenda that could affect hiring plans for tech and other skilled-work employers. Local Business Climate: Massachusetts lawmakers approved extending outdoor drinking and “last call” rules for summer events, aiming to boost foot traffic during the World Cup and MA250. Sports Business: The PWHL’s expansion team in Detroit is set to land Hilary Knight via a sign-and-trade, with Boston as her former home.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
